NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Caregivers of people with advanced cancer often find that psychedelic-assisted therapy can strengthen their relationships and provide a sense of hope during difficult times.
Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study
About 1 in 15 young adults in the United States reported microdosing hallucinogens in the past year.
Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
Low doses of psilocybin may reduce the frequency of migraine attacks, but a two-dose "pulsed" schedule did not show a significant advantage over a single dose in this trial.
Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
Microdosing psilocybin can improve the quality of creative thinking by helping people come up with more original ideas.
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial
Participants with major depressive disorder reported feeling more motivated, more connected to others, and better able to process emotions during an eight-week LSD microdosing trial.
Ayahuasca, Personality, and Quality of Life: What Changes After an Amazonian Retreat
A prospective longitudinal study with 264 participants documents lasting changes in personality, quality of life and decentering following Shipibo-led ayahuasca retreats in the Peruvian Amazon.
Compass, Transcend, and Usona Identified as Receivers of Priority Vouchers Following Psychedelics Executive Order
Compass Pathways, Transcend Therapeutics, and the Usona Institute have been named the first recipients of FDA National Priority Vouchers following last week’s landmark executive order, for programs developing psilocyb...
Protests Highlighting Conflict in Gaza Disrupt Psychedelic Culture Conference
Pointed conversations between protesters and MAPS founder Rick Doblin at the Psychedelic Culture Conference in San Francisco amplified disagreements and shared perspectives about the conflict in Gaza. The post Protest...
Learning to Die Well: Inside a Psychedelic End‑of‑Life Retreat
What if learning how to die well is also how we learn to live? Inside a psychedelic end‑of‑life retreat rooted in the teachings of Ram Dass and a growing movement toward conscious dying. The post Learning to Die Well:...
Trump Signs Executive Order To Fast-Track Psychedelic Research
President Donald Trump signed an executive order aimed at accelerating clinical research and federal approval for psychedelic therapies especially ibogaine as mental health therapy for veterans. The post Trump Signs E...
New Orleans Hosts Psychedelic Research Conference Double-Header
Over the last week in February, more than 200 people from psychedelic drug development companies, clinical researchers, regulators, and investors gathered in New Orleans to attend the 6th Annual Psychedelic Therapeuti...
New Federal Bill Aims to Establish VA Office of Novel Therapeutics
The Veterans Health Administration Novel Therapeutics Preparedness Act is the fourth psychedelics-related bill filed in Congress this term as related legislation gains momentum. The post New Federal Bill Aims to Estab...
Europe’s Regulatory Body Signals Shift To ‘Weight of Evidence’ Model For Drug Approvals—How Does It Affect Psychedelic Medicines?
The European Medicines Agency is taking steps to rethink how certain high-need medicines reach patients, with a new concept paper proposing a more flexible, evidence-based pathway for cancer therapies. The post Europe...
Federal Support for U.S. Psychedelic Research Accelerates 5-MeO-DMT Clinical Trials
The rescheduling of cannabis by executive order and the FDA's acceleration of research into potential 5-MeO-DMT therapies reflects expanded federal support for clinical investigations into psychedelic-assisted treatme...